BioCryst Pharmaceuticals (BCRX) Q4 2025 earnings summary

Executive summary

• Achieved record 2025 revenue and first full-year profitability, driven by strong U.S. ORLADEYO growth, strategic portfolio expansion, and the acquisition of Astria Therapeutics, which added navenibart to the HAE pipeline.

• Completed sale of European ORLADEYO business in October 2025, improving profitability and focusing on the U.S. market.

• Maintained a strong balance sheet and disciplined capital allocation, supporting sustainable growth in rare diseases.

• Positioned for durable revenue growth with new product launches, late-stage pipeline assets, and high cash flow visibility.

Financial highlights

• Full-year 2025 ORLADEYO revenue reached $601.8 million (GAAP), up 38% year-over-year and 43% excluding Europe; total revenues were $874.8 million, with non-GAAP total revenues at $592.9 million (+45% y-o-y).

• Operating profit for 2025 was $341 million (GAAP), $214 million (non-GAAP, ex-EU), up 198% year-over-year.

• Ended 2025 with $337.5 million in cash and investments; $400 million financing facility secured.

• Paid off Pharmakon Term Loan ($323.7 million), reducing interest expense by 20% year-over-year.

• ORLADEYO direct revenue surpassed the zero-royalty tier, reducing future royalty burden.

Outlook and guidance

• 2026 ORLADEYO revenue guidance set at $625–$645 million; total revenue guidance at $635–$660 million.

• 2026 non-GAAP operating expenses expected between $450–$470 million, including Astria expenses.

• HAE franchise projected to generate double-digit revenue growth into the next decade, with $1B+ cash balance by 2029.

• R&D costs expected to rise in 2026 due to late-stage navenibart development, then decline post-completion.

• Committed to maintaining profitability and driving cash flow generation.